Fung C, 2015, Journal of Clinical Oncology (Link to abstract)
This European population-based study quantifies the CVD mortality amongst 15,006 men with testicular non-seminoma over a 30 year period (1980-2010) when cisplatin-based chemotherapy became widely adopted. The authors report a significantly increased CVD mortality after chemotherapy (Standardized Mortality Ratio 1.36) but not surgery. In particular they note a significant excess of deaths in the first year after diagnosis (SMR 5.31) and included cerebrovascular disease (SMR 3.45) and heart disease (SMR 3.45), with distant disease and older age being identified as risk factors.
*Think about possibility of CVD in our TYA population with metastatic testicular GCTs even early post chemotherapy, particularly those with identifiable risk factors. Remember VTE prophylaxis.